2017 Collins News Today : Breaking News, Live Updates & Top Stories | Vimarsana

News, analysis and interviews with politicians and observers. When the public trial for the drug was about to be announced as a failure. Want to read a little from the complaint. Mis 416 had the potential to be an enormously profitable if the drug trial was successful. The drug, however, failed the drug trial. Public announcement of these results caused the stock price to drop by 92 . In or about june of 2017, Christopher Collins violated the duties he owed to innate by Passing Material Nonpublic information regarding the Drug Trial Results to his son the defendant so that Cameron Collins coul...

Interviews with political figures and news updates. Interviews with political figures and news updates. Able to sell the shares. They have telephone logs, who called whom and when. It appears they have people helping the government out with the testimony. As mimi said, andrea, its kind of overwhelming evidence thats difficult for federal prosecutors to ignore. And chuck todd, weve not yet seen to my knowledge a tweet from the president or any suggestion that this is witch hunt, mueller related. But this is really separate, this is an investigation that started, there was an Ethics Investigatio...

>> thank you, geoff. good afternoon, everybody. u.s. representative christopher collins sat on innate's board of directors for a period of more than three years. spanning the run-up to the drug trial announcement in mid-2017. collins himself was the company's largest shareholder. in or about the summer of 2017, a drug designed to treat a debilitating form of multiple sclerosis had entered the late stages of a phase 2b clinical trial. this drug, mis-416, was the only viable drug in the pipeline for innate. this is significant in that the company's value was nearly completely wrapped up in the s...

>> thank you, geoff. and good afternoon, everybody. u.s. representative christopher collins sat on innate's board of directors for a period of more than three years, spanning the run-up to the drug trial announcement in mid-2017. collins himself was the company's largest shareholder. in or about the summer of 2017, a drug designed to treat a debilitating form of multiple sclerosis had entered the late stages of a phase ii clinical trial. this drug, mis-416, was the only viable drug in the pipeline for innate. this is significant in that the company's value was nearly completely wrapped up in t...